[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"stage-iib-cervical-cancer-radical-radiotherapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:stage-iib-cervical-cancer-radical-radiotherapy":39},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":4},"100612159",false,"NCT07249957","Reducing Radiation Target Volume for Stage IIb Cervical Cancer","Reducing Radiation Target Volume in Radical Radiotherapy for Stage IIb Cervical Cancer: A Single-arm Exploratory Study","Inclusion Criteria:\n\n1. The patient voluntarily participated in this study and signed the informed consent form;\n2. Age range: 50 to 75 years old;\n3. Patients with cervical cancer who had not undergone surgery or chemotherapy and were initially diagnosed with squamous cell carcinoma by pathological histology, and were HPV high-risk positive;\n4. According to the 2018 International Federation of Gynecology and Obstetrics (FIGO) staging system, it was stage IIb (tumor size \\\u003C 4 cm);\n5. ECOG score: 0 to 1, with an expected survival of more than 6 months;\n6. Pregnant women must undergo a pregnancy test (serum or urine) 7 days before enrollment, and the result must be negative, and they are willing to use appropriate contraceptive methods during the trial;\n7. According to the investigator's judgment, there are no absolute contraindications to radiotherapy and chemotherapy or surgery, and they can comply with the trial protocol.\n\nExclusion Criteria:\n\n1. Active or uncontrolled severe infections;\n2. Cirrhosis, decompensated liver disease;\n3. History of immunodeficiency, including HIV positive or having other acquired congenital immune deficiency diseases;\n4. Chronic renal insufficiency and renal failure;\n5. Patients with other malignancies that require treatment and\u002For newly diagnosed within 5 years;\n6. Myocardial infarction, severe arrhythmia, and ≥ grade 2 congestive heart failure (NYHA classification);\n7. Patients who have undergone pelvic artery embolization;\n8. Patients who have received radiotherapy for pelvic malignant tumors in the past;\n9. Patients who have received partial hysterectomy or radical hysterectomy in the past;\n10. Patients with a history of severe allergic reaction to platinum-based chemotherapy drugs;\n11. Comorbidities, requiring the use of drugs that cause significant liver and kidney damage during treatment, such as tuberculosis, etc.;\n12. Patients who cannot understand the experimental content and cannot cooperate, or who refuse to sign the informed consent form;\n13. Patients with serious accompanying diseases or other special conditions that seriously endanger their safety or affect their ability to complete the study.","FEMALE","50 Years","75 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"NA","This is a domestic single-center prospective clinical trial. The study selected patients with histologically confirmed cervical squamous cell carcinoma, diagnosed as stage IIb according to the FIGO 2018 staging principle (tumor size \\\u003C 4 cm). The patients first received 6 cycles of induction chemotherapy (carboplatin (AUC2) + paclitaxel (80 mg\u002Fm2), q1w), followed by concurrent chemoradiotherapy with a platinum-based regimen. The external beam radiation field only covered the entire uterus (including the primary lesion of the cervix), the bilateral parametrium, and the lesion of the cervix\u002Fvagina extending 3 cm downward. A total of 60 participants are planned to be included in the study.",[26],"Stage IIb Cervical Cancer Radical Radiotherapy","NOT_YET_RECRUITING","2025-11-18",{"date":30,"type":31},"2025-11-25","ACTUAL",{"date":33,"type":20},"2025-11",{"date":35,"type":20},"2029-10",{"name":37,"class":38},"Chongqing University Cancer Hospital","OTHER",""]